Precision medicine in rheumatoid arthritis: are we there yet?

Salomon-Escoto, Karen

doi:10.1007/s10067-019-04766-0

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 The primary goals of precision medicine are to identify accurate and earlier indicators of health trajectories for individuals, detect early stages of the disease, reverse disease development, slow disease progression and adjust health trajectories through targeted and more effective pharmacological treatments or lifestyle interventions. 5 Precision medicine encompasses multiple layers of precision, with patient history and lab tests considered to improve tailoring of treatment to the individual. A newer and more narrow approach to precision medicine involves the use of biomarkers: multidimensional sources of patient data that mainly include ‘omics’ (genomics, epigenomics, transcriptomics, proteomics, metabolomics, metagenomics, etc) to generate prediction algorithms.…”

Section: Introductionmentioning

confidence: 99%

“…In the future, precision medicine may enable treatment that is highly personalised and tailored for patient management 4. The primary goals of precision medicine are to identify accurate and earlier indicators of health trajectories for individuals, detect early stages of the disease, reverse disease development, slow disease progression and adjust health trajectories through targeted and more effective pharmacological treatments or lifestyle interventions 5. Precision medicine encompasses multiple layers of precision, with patient history and lab tests considered to improve tailoring of treatment to the individual.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Making space for patients’ preferences in precision medicine: a qualitative study exploring perspectives of patients with rheumatoid arthritis

et al. 2022

View full text Add to dashboard Cite

ObjectivePrecision medicine in rheumatoid arthritis (RA) creates new opportunities to involve patients in early identification of accurate indicators of health trajectories. The aim of this study was to explore patient perspectives on patient-centredness in precision medicine for RA treatment.DesignSemistructured interviews were conducted to explore patients’ perspectives on a new personalised approach to RA treatment. The interview guide was developed together with patient research partners and health care professionals.SettingAn invitation to the interviews was sent through a mobile application. The interviews were one-on-one, using an interview guide with open-ended questions. Interviews were conducted digitally (October 2020–February 2021) via Zoom or telephone, depending on each participant’s preferences.ParticipantsPatients with RA (N=12) were purposively recruited. Patients were eligible if they had an RA diagnosis, were aged 18–80 years, and understood and expressed themselves in Swedish. Participants and researchers did not know each other prior to the interviews.ResultsParticipants expressed desires and needs for patients to have an active role in precision medicine by making shared treatment decisions together with a healthcare professional. In order for that to work, patients need information on potential treatment options, an ability to express their preferences, an individual treatment plan and identification of personal treatment goals. Patients also identified two requirements of healthcare professional in precision medicine: a safe environment to express personal matters and two-way communication with healthcare professionals.ConclusionCommunication between patients and healthcare professionals needs to be more focused on patients’ individual treatment preferences and expressed needs, in order to increase patient-centredness in treatment decisions, so shared decision-making can become a reality. More research is needed to design multifaceted implementation strategies to support patients and healthcare professionals to increase patient-centredness throughout treatment personalisation.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Making space for patients’ preferences in precision medicine: a qualitative study exploring perspectives of patients with rheumatoid arthritis

et al. 2022

View full text Add to dashboard Cite

show abstract

The maximum dose and duration in the therapy single use methotrexate to achieve remission by rheumatoid arthritis patients through disease activity score 28 (DAS28)

Soeroso

Rahmayanti

Suryana

2021

Journal of Basic and Clinical Physiology and Pharmacology

View full text Add to dashboard Cite

Objectives One of the treatments for rheumatoid arthritis (RA) was methotrexate which a disease modifying antirheumatic drug therapy. The use of methotrexate required the right dose and length of therapy to achieve remission. The effectivity of methotrexate could be accounted by disease activity score 28 (DAS28) as a tool has been used clinically with a combination number of tender joints, swollen joints, erythrocyte sedimentation rate, and global clinical assessment by the patient. The aim of this study was to determine the effective dose and length of therapy methotrexate was measured by DAS28 score. Methods This research was a cross-sectional study and data was collected from patient medical records in Saiful Anwar Hospital, Malang, from February to July 2018. The research has been given ethical clearance. The inclusion criteria for the 88 subjects were men and women, over 20 years of age, usage of only methotrexate for at least three months, an erythrocyte sedimentation rate score, uncomplicated inflammatory bowel disease, cancer, and systemic lupus erythematosus. All data obtained was entered in formula DAS28. The Statistic analysis used both Pearson and Spearman’s rank correlation. Results Only 16 patients achieved remission. There were not significant correlation in statistical analysis between DAS score and cumulative dose (r=−0.091; p=0.400), average dose (r=0.043; p = 0.692), maximum dose (r=0.074; p=0.492), and length of therapy (r=−0.075; p = 0.489). The initial dose of therapy methotrexate was different and the length of therapy was adjusted to the patient’s health condition. Conclusions The maximum dose and length of therapy methotrexate was required to achieve remission in RA.

show abstract

Precision medicine in rheumatoid arthritis: are we there yet?

Cited by 2 publications

References 16 publications

Making space for patients’ preferences in precision medicine: a qualitative study exploring perspectives of patients with rheumatoid arthritis

Making space for patients’ preferences in precision medicine: a qualitative study exploring perspectives of patients with rheumatoid arthritis

The maximum dose and duration in the therapy single use methotrexate to achieve remission by rheumatoid arthritis patients through disease activity score 28 (DAS28)

Contact Info

Product

Resources

About